SAVA Jumps From $7 To $75 In Just 3 Weeks, DRRX Gets FDA Nod, IMVT Pauses Trials, OCGN Catches Eye

(RTTNews) – Today’s Daily Dose brings you news about encouraging results of Cassava’s Alzheimer’s trial; FDA approval of DURECT’s post-operative pain relief depot product, Posimir, Immunovant pausing IMVT-1401 trials and Travere’s pivotal study of Sparsentan in focal segmental glRead MoreMarketsMarkets Feed